Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor

Blood

Volumn 92, Issue 2, 1998, Pages 496-506

  Jacquemin, Marc G ^a   Desqueper, Benoît G ^b   Benhida, Abdellah ^b   Elst, Luc Vander ^a   Hoylaerts, Marc F ^b   Bakkus, Marleen ^a   Thielemans, Kris ^b   Arnout, Jef ^b   Peerlinck, Kathelijne ^b   Gilles, Jean Guy G ^a   Vermylen, Jos ^a   Saint Remy, Jean Marie R ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BO2C11; PHOSPHOLIPID; PROCOAGULANT; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANTIBODY PRODUCTION; ARTICLE; CASE REPORT; ENZYME INACTIVATION; HEMOPHILIA; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 0032528496     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.2.496     Document Type: Article

References (50)

1. Rizza CR, R Biggs: The treatment of patients who have factor VIII antibodies. Br J Haematol 24:65,1973
2. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J: The natural history of factor VIII:C inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 71:344,1988
3. Tuddenham EGD, Schwaab R, Seehafer S: Haemophilia A: Database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 22:3511,1994
4. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EG, Oldenburg J: Haemophilia A: Mutation type determines risk of inhibitor formatioa Thromb Haemost 74:1402,1995
5. Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P: Factor VIII gene inversions in severe hemophilia A: Results of an international consortium study. Blood 86:2206,1995
6. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN: Structure of human factor VIII. Nature 312:337, 1984
7. Arai M, Scandella D, Hoyer LW: Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 83:1978,1989
8. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS: Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 75:1999,1990
9. Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H: A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 69:240,1993
10. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D: A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 269:11601,1994
11. Saenko EL, Scandella D: A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem 270:13826,1995
12. Weiss HJ, Sussman II, Hoyer LW: Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 60:390,1977
13. Hamer RJ, Koedam JA, Beeser-Visser NH, Bertina RM, Van Mourik JA, Sixma JJ: Factor VIII binds to von Willebrand factor via its Mr 80,000 light chain. Eur J Biochem 166:37,1987
14. Fulcher C, de Graaf Mahoney S, Roberts J, Kasper C, Zimmerman T: Localisation of human factor VIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sei USA 82:7728,1985
15. Scandella D, Graaf Mahoney S, Mattingly M, Roeder D, Timmons L, Fulcher C: Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of fVIII fragments expressed in Escherichia Coli. Proc Natl Acad Sei USA 85:6152,1988
16. Fulcher C, De Graaf Mahoney S, Zimmerman T: Factor VIII inhibitor IgG subclass and fVIII polypeptide specificity determined by immunoblotting. Blood 69:1475, 1987
17. Lollar P, Parker ET, Curtis JE, Helgerson SL, Hoyer LW, Scott ME, Scandella D: Inhibition of human factor Villa by anti-A2 subunit antibodies. J Clin Invest 93:2497, 1994
18. Gilles JG, Arnout J, Vermylen J, Saint-Remy JMR: Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 82:2452,1993
19. Shima M, Nakai H, Scandella D, Tanaka I, Sawamoto Y, Kamisue S, Morichika S, Murakami T, Yoshioka A: Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol 91:714,1995
20. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E: Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipidbinding site. Blood 86:1811,1995
21. Saenko EL, Shima M, Gilbert G, Scandella D: Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 271:27424,1996
22. de la Fuente B, Hoyer LW: The idiotypic characteristics of human antibodies to factor VIII. Blood 64:672,1984
23. Sultan Y, Kazatchikine M, Maisonneuve P, Nydegger U: Antiidiotypic suppression of auto-antibodies to factor VIII (anti-hemophilic factor) by high dose intravenous gammaglobulin. Lancet 2:765,1984
24. Lubahn BC, Reisner HM: Characterization of a monoclonal anti-idiotype antibody to human anti-factor VIII antibodies. Proc Natl Acad Sei USA 87:8232,1990
25. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JMR: Neutralising anti-idiotypic antibodies to factor VIII inhibitors following desensitization in patients with hemophilia A. J Clin Invest 97:1382, 1996
26. Littlewood JD, Bevan SA, Kemball-Cook G, Evans RJ, Barrowcliffe TW: Variable inactivation of human factor VIII from different sources by human factor VIII inhibitors. Br J Haematol 77:535,1991
27. Gawryl M, Hoyer L: Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 60:1103, 1982
28. Amano K, Arai M, Koshihara K, Suzuki T, Kagawa K, Nishida V, Fukutake K: Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex. Am J Hematol 49:310,1995
29. Griffin BD, Micklem LR, McCann MC, James K, Pepper DS: The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII. Thromb Haemost 55:40,1986
30. Banchereau J, Rousset F: Growing human B lymphocytes in the CD40 system. Nature 353:678, 1991
31. Peltz GA, Trounstine ML, Moore KW: Cloned and expressed human Fc receptor for IgG mediates anti-CDS-dependent lymphoproliferation. J Immunol 141:1891,1988
32. Planken EV, Dijkstra NH, Bakkus MH, Willemze R, KluinNelemans JC: Proliferation of precursor B-Iineage acute lymphoblastic leukaemia by activating the CD40 antigen. Br J Haematol 95:319, 1996
33. Madec AM, Rousset F, Ho S, Robert F, Thivolet C, Orgiazzi J, Lebecque S: Four IgG anti-islet human monoclonal antibodies isolated from a type 1 diabetes patient recognize distinct epitopes of glutamic acid decarboxylase 65 and are somatically mutated. J Immunol 156:3541,1996
34. Bakkus MH, Heirman C, Van-Riet I, Van-Camp B, Thielemans K: Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80:2326, 1992
35. Grieco F, Hay JM, Hull R: An improved procedure for the purification of protein fused with glutathione S-transferase. Biotechniques 13:856,1992
36. Bloom JW: The interaction of rDNA factor VIII, factor VIHdes-797-1562 and factor VIIIdes-797-1562-derived peptides with phospholipid. Thromb Res 48:439,1987
37. Kasper CK, Aledort LM, Aronson D, Counts R, Edson JR. van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:869,1975
38. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E: The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability. Thromb Haemost 73:247,1995
39. O'Shanessy DJ, Brigham-Burke MB, Soneson KK, Hensley P, Brooks I: Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: Use of nonlinear least squares analysis methods. Anal Biochem 212:457,1993
40. Vlot AJ, Koppelman SJ, Meijers JC, Dama C, van den Berg HM, Bouma BN, Sixma JJ, Willems GM: Kinetics of factor VIII-von Willebrand factor association. Blood 87:1809,1996
41. Leyte A, Verbeet MP, Brodniewicz-Proba T, Van Mourik JA, Mertens K: The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. Biochem J 257:679,1989
42. Snow ME, Amzel LM: A molecular-mechanics study of the conformation of the interchain disulfide of human immunoglobulin G4 (IgG4). Mol Immunol 25:1019, 1988
43. Lollar P, Parker ET: Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J BiolChem 266:12481,1991
44. Sjamsoedin L, Heijnen L, Mauser-Bunschoten EP: The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII: A double-blind clinical trial. N Engl J Med 305:717,1981
45. Hedner U, Glazer S, Falch J: Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Trans Med Rev 7:78,1993
46. Demaison C, Chastagner P, Thèze J, Zouali M: Somatic diversification in the heavy chain variable region genes expressed by human autoantibodies bearing a lupus-associated nephritogenic anti-DNA idiotype. Proc Natl Acad Sei USA91:514,1994
47. Sugimoto M, Dent J, McClintock R, Ware J, Ruggeri ZM: Analysis of structure-function relationship in the platelet membrane glycoprotein Ib-binding domain of von Willebrand factor by expression of deletion mutants. J Biol Chem 266:12185,1993
48. Lollar P: Analysis of factor VIII inhibitors using hybrid human/ porcine factor VIII. Thromb Haemost 78:647,1997
49. Klinman NR: In vitro analysis of the generation and propagation of memory B cells. Immunol Rev 150:91,1996
50. Banchereau J, Rousset F: Human B lymphocytes: Phenotype, proliferation, and differentiation. Adv Immunol 52:125,1992